Xinhua News Agency, Beijing, June 25th (Zhuang Yingna, Shao Longfei) The novel coronavirus mRNA vaccine (ARCoV), which was jointly developed by the Institute of Military Medicine of the Academy of Military Sciences and local enterprises, was officially approved by clinical trials in National Medical Products Administration on the 19th. This is the first COVID-19 mRNA vaccine approved for clinical trial in China.
Since the outbreak of the COVID-19 epidemic, the Institute of Military Medicine of the Academy of Military Sciences has deployed emergency scientific research to tackle key problems, and at the same time promoted the research and development of vaccines in COVID-19 with multiple technical routes. COVID-19 mRNA vaccine made in China is another high-tech vaccine variety approved for clinical trial after recombinant COVID-19 vaccine (adenovirus vector) in our hospital.
According to Qin Chengfeng, the project leader and researcher of the institute, mRNA vaccine is a new vaccine form in recent years. Its basic principle is to introduce mRNA expressing antigen target into the body through a specific delivery system, express protein in the body and stimulate the body to produce specific immune response, thus enabling the body to obtain immune protection.
关于作者